Tumour vaccines expressing IL-2, CD80, and IL-2 plus CD80 gene

International Journal of Oncology

Volumn 11, Issue 6, 1997, Pages 1213-1219

  Bubeník, Jan ^a   Rössner, Pavel ^a   Bubeníková, Dana ^a   Símová, Jana ^a   Indrová, Marie ^a   Sloncová, Eva ^a  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

CD80; Gene therapy; Interleukin 2; Tumour vaccines

Indexed keywords

B7 ANTIGEN; INTERLEUKIN 2; TUMOR VACCINE;

ANIMAL CELL; ARTICLE; CANCER IMMUNOLOGY; CANCER PREVENTION; DRUG EFFICACY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; TUMOR;

EID: 0030782242     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.11.6.1213     Document Type: Article

References (6)

1. Boon T, Cerrotini JC and van den Eynde B: Tumor antigens recognized by T lymphocytes. Ann Rev Immunol 12: 337-365, 1994.
2. Bubeník J: Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol Ther 69: 1-14, 1996.
3. Bubeník J: Gene transfer for immunotherapy of cancer (editorial). Gene Ther 3: 944-945, 1996.
4. Salvatori S, Gansbacher B, Wernick I, Tirelli S and Zier K: B7.1 amplifies the response to interleukin-2-secreting tumour vaccines in vivo, but fails to induce a response by naive cells in vitro. Hum Gene Ther 6: 1299-1306, 1995.
5. +-mediated rejection of established tumours. Hum Gene Ther 8: 477-488, 1997.
6. Cayeux S, Richter G, Decker C, Beck C, Aicher A, Pezzutto A, Dürken B and Blankenstein T: Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency. Eur J Immunnol 27: 1657-1662, 1997.